 CA-19-9 Antigen
"CA-19-9 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
| Descriptor ID |
D018395
|
| MeSH Number(s) |
D23.050.285.050.119 D23.050.301.290.544.119 D23.050.550.325.119 D23.050.705.230.544.119 D23.101.140.075.119
|
| Concept/Terms |
CA-19-9 Antigen- CA-19-9 Antigen
- Antigen, CA-19-9
- CA 19 9 Antigen
- CA 19.9 Antigen
- Antigen, CA 19.9
- Gastrointestinal Cancer Antigen
- Cancer Antigen, Gastrointestinal
- CA 19-9 Antigen
- Antigen, CA 19-9
- Antigen CA-19-9
- Antigen CA 19 9
- CA-19-9, Antigen
|
Below are MeSH descriptors whose meaning is more general than "CA-19-9 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CA-19-9 Antigen".
This graph shows the total number of publications written about "CA-19-9 Antigen" by people in this website by year, and whether "CA-19-9 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "CA-19-9 Antigen" by people in Profiles.
-
Sugawara T, Rodriguez Franco S, Sherman S, Kirsch MJ, Colborn K, Franklin O, Ishida J, Grandi S, Al-Musawi MH, Gleisner A, Schulick RD, Del Chiaro M. Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database. Pancreatology. 2024 Dec; 24(8):1340-1347.
-
Coppola A, La Vaccara V, Farolfi T, Asbun HJ, Boggi U, Conlon K, Edwin B, Ferrone C, Jonas E, Kokudo N, Perez EM, Satoi S, Sparrelid E, Stauffer J, Zerbi A, Takemura N, Lai Q, Almerey T, Bernon M, Cammarata R, Djoumi Y, Gallagher T, Ghorbani P, Ginesini M, Hashimoto D, Kauffmann EF, Kleive D, Llu?s N, Gonz?lez RM, Napoli N, Nappo G, Nebbia M, Ricchitelli S, Sahakyan MA, Yamamoto T, Coppola R, Caputo D. Preoperative carbohydrate antigen 19.9 level predicts lymph node metastasis in resectable adenocarcinoma of the head of the pancreas: a further plea for biological resectability criteria. Int J Surg. 2024 Oct 01; 110(10):6092-6099.
-
Kobayashi K, Ono Y, Kitano Y, Oba A, Sato T, Ito H, Mise Y, Shinozaki E, Inoue Y, Yamaguchi K, Saiura A, Takahashi Y. Prognostic Impact of Tumor Markers (CEA and CA19-9) on Patients with Resectable Colorectal Liver Metastases Stratified by Tumor Number and Size: Potentially Valuable Biologic Markers for Preoperative Treatment. Ann Surg Oncol. 2023 Nov; 30(12):7338-7347.
-
Piper M, Ross RB, Hu J, Watanabe S, Knitz M, Mehrotra S, Shulick R, Chiaro MD, Karam SD. Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma. Int J Radiat Oncol Biol Phys. 2023 07 01; 116(3):627-639.
-
Ono Y, Inoue Y, Ito H, Sasaki T, Takeda T, Ozaka M, Sasahira N, Hiratsuka M, Matsueda K, Oba A, Sato T, Saiura A, Takahashi Y. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels. HPB (Oxford). 2023 01; 25(1):100-108.
-
Pozzi Mucelli RM, Moro CF, Del Chiaro M, Valente R, Blomqvist L, Papanikolaou N, L?hr JM, Kartalis N. Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria? Eur Radiol. 2022 Aug; 32(8):5144-5155.
-
Omiya K, Oba A, Inoue Y, Kobayashi K, Wu YHA, Ono Y, Sato T, Sasaki T, Ozaka M, Sasahira N, Ito H, Saiura A, Takahashi Y. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Ann Surg. 2023 06 01; 277(6):e1278-e1283.
-
Oba A, Croce C, Hosokawa P, Meguid C, Torphy RJ, Al-Musawi MH, Ahrendt S, Gleisner A, Schulick RD, Del Chiaro M. Prognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines. Ann Surg. 2022 01 01; 275(1):175-181.
-
Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, Honda G, Uemura K, Okada KI, Matsumoto I, Nagai M, Yanagimoto H, Kurata M, Fukumoto T, Mizuma M, Yamaue H, Unno M. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer. 2019 Mar 21; 19(1):252.
-
Motoi F, Murakami Y, Okada KI, Matsumoto I, Uemura K, Satoi S, Sho M, Honda G, Fukumoto T, Yanagimoto H, Kinoshita S, Kurata M, Aoki S, Mizuma M, Yamaue H, Unno M. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. World J Surg. 2019 Feb; 43(2):634-641.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|